Pharsight

Sotylize is owned by Azurity.

Sotylize contains Sotalol Hydrochloride.

Sotylize has a total of 3 drug patents out of which 0 drug patents have expired.

Sotylize was authorised for market use on 22 October, 2014.

Sotylize is available in solution;oral dosage forms.

Sotylize can be used as sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm, sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently in sinus rhythm; indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that in the judgement of the physician are life-threatening.

The generics of Sotylize are possible to be released after 31 August, 2035.

Patent Number	Company	Patent Title	Patent Expiry
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10206895	AZURITY	Sotalol compositions and uses of the same	Apr, 2034 (10 years from now)
US11013703	AZURITY	Sotalol compositions and uses of the same	Apr, 2034 (10 years from now)
US9724297	AZURITY	Sotalol compositions and uses of the same	Aug, 2035 (12 years from now)

Do you want to check out SOTYLIZE patents from before 2022?

Drugs and Companies using SOTALOL HYDROCHLORIDE ingredient

Market Authorisation Date: 22 October, 2014

Treatment: Sotylize is indicated for the maintenance of normal sinus rhythm [delay in time to recurrence of atrial fibrillation/atrial flutter (afib/afl)] in patients with symptomatic afib/afl who are currently ...

Dosage: SOLUTION;ORAL